Brought to you by 
Reata nets $492mm through public offering
19 Nov 2019
Executive Summary
Reata Pharmaceuticals Inc. netted $492mm through a public offering of 2.76mm Class A common shares (including the overallotment) at $183. Proceeds will support continued development and future commercialization of lead candidates bardoxolone (Phase III for chronic kidney disease caused by Alport syndrome) and omaveloxolone (Phase II for Friedreich's ataxia). Money will also be used to make payments due to AbbVie following Reata's reacquisition of all rights to bardoxolone and omaveloxolone earlier this year. (AbbVie had global rights (excluding US and Asia) to the candidate under a 2010 deal, which Reata terminated in October. It now owes AbbVie $330mm, primarily for the rights to bardoxolone.)
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Reata nets $492mm through public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice